PMID- 32267076
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 22 Suppl 1
IP  - Suppl 1
DP  - 2020 Apr
TI  - Dedicated kidney disease-focused outcome trials with sodium-glucose 
      cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, 
      DAPA-CKD, and EMPA-KIDNEY.
PG  - 46-54
LID - 10.1111/dom.13987 [doi]
AB  - In the past decade, many cardiovascular outcome trials (CVOT) on the efficacy and 
      safety of glucose-lowering agents have been completed. Amongst newer agents 
      available for treatment of type 2 diabetes mellitus (T2DM), sodium-glucose 
      cotransporter-2 (SGLT2) inhibitors have garnered much attention in contemporary 
      clinical practice due to observed benefits on cardiovascular and kidney outcomes 
      among patients with T2DM, as reported in large randomized controlled trials 
      (RCT). These findings are reflected in the updated clinical guidelines of several 
      major professional societies. Herein, we briefly review the mechanism of action 
      of SGLT2 inhibitors and their pleiotropic effects, summarize key findings and 
      limitations of initial CVOTs, then discuss three major kidney disease-focused 
      outcome trials, including the Canagliflozin and Renal Events in Diabetes and 
      Established Nephropathy Clinical Evaluation (CREDENCE) trial as well as two 
      ongoing RCTs: Dapagliflozin and Prevention of Adverse Outcomes in Heart 
      Failure-chronic kidney disease and EMPA-KIDNEY.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Rhee, Jinnie J
AU  - Rhee JJ
AUID- ORCID: 0000-0001-8990-0379
AD  - Division of Nephrology, Department of Medicine, Stanford University School of 
      Medicine, Stanford, California, United States.
AD  - Stanford Diabetes Research Center, Stanford University School of Medicine, 
      Stanford, California, United States.
FAU - Jardine, Meg J
AU  - Jardine MJ
AD  - The George Institute for Global Health, UNSW, Sydney, New South Wales, Australia.
AD  - Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, 
      Australia.
FAU - Chertow, Glenn M
AU  - Chertow GM
AD  - Division of Nephrology, Department of Medicine, Stanford University School of 
      Medicine, Stanford, California, United States.
AD  - Stanford Diabetes Research Center, Stanford University School of Medicine, 
      Stanford, California, United States.
AD  - Department of Epidemiology and Population Health, Stanford University School of 
      Medicine, Stanford, California, United States.
FAU - Mahaffey, Kenneth W
AU  - Mahaffey KW
AD  - Stanford Diabetes Research Center, Stanford University School of Medicine, 
      Stanford, California, United States.
AD  - Division of Cardiovascular Medicine, Stanford University School of Medicine, 
      Stanford, California, United States.
AD  - Stanford Center for Clinical Research, Stanford University School of Medicine, 
      Stanford, California, United States.
LA  - eng
GR  - K01 DK110221/DK/NIDDK NIH HHS/United States
GR  - K24 DK085446/DK/NIDDK NIH HHS/United States
GR  - Medical Research Future Fund Next Generation Clinical Researchers Program Career 
      Development Fellowship/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 9NEZ333N27 (Sodium)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucose
MH  - Humans
MH  - Kidney
MH  - Motivation
MH  - *Renal Insufficiency, Chronic/drug therapy
MH  - Sodium
PMC - PMC8018526
MID - NIHMS1682575
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - chronic kidney disease
OT  - clinical trials
OT  - diabetes
OT  - kidney outcomes
COIS- CONFLICT OF INTERESTS M.J.J. is responsible for research projects that have 
      received unrestricted funding from Gambro, Baxter, CSL, Amgen, Eli Lilly, and 
      Merck; has served on advisory boards sponsored by Akebia, Baxter, and Boehringer 
      Ingelheim; and spoken at scientific meetings sponsored by Janssen, Amgen, and 
      Roche, with any consultancy, honoraria or travel support paid to her institution. 
      G.M.C. serves on the Steering Committee for DAPA-CKD and served as a national 
      leader for CREDENCE. K.W.M.'s financial disclosures can be viewed at 
      http://med.stanford.edu/profiles/kenneth-mahaffey.
EDAT- 2020/04/09 06:00
MHDA- 2021/06/25 06:00
PMCR- 2021/04/02
CRDT- 2020/04/09 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/01/22 00:00 [revised]
PHST- 2020/01/30 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2021/04/02 00:00 [pmc-release]
AID - 10.1111/dom.13987 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2020 Apr;22 Suppl 1(Suppl 1):46-54. doi: 10.1111/dom.13987.